MMED (NASDAQ:MMED) Coverage Initiated at Wells Fargo & Company

Equities researchers at Wells Fargo & Company assumed coverage on shares of MMED (NASDAQ:MMED) in a research note issued on Tuesday. The firm set an “overweight” rating and a $26.00 price target on the stock. Wells Fargo & Company‘s target price points to a potential upside of 81.18% from the stock’s previous close.

Several other research analysts have also weighed in on MMED. Mizuho assumed coverage on shares of MMED in a research report on Tuesday. They set an “outperform” rating and a $21.00 target price on the stock. Citigroup assumed coverage on MMED in a research note on Tuesday. They set a “buy” rating and a $23.00 price target on the stock. Bank of America started coverage on MMED in a research note on Tuesday. They issued a “buy” rating and a $27.00 price objective for the company. Wall Street Zen raised MMED to a “hold” rating in a report on Saturday, March 14th. Finally, Morgan Stanley assumed coverage on MMED in a research note on Tuesday. They set an “overweight” rating and a $19.00 price target for the company. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $22.33.

MMED Stock Down 0.8%

NASDAQ:MMED opened at $14.35 on Tuesday. MMED has a fifty-two week low of $14.10 and a fifty-two week high of $20.48.

MMED Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.